Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: A randomized, double-blind, controlled, parallel-group, Phase 2b trial: Discussions from a Twitter journal club @respandsleepjc (#rsjc)

Christopher Kawala,Anju Anand,Matthew B. Stanbrook

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: A randomized, double-blind, controlled, parallel-group, Phase 2b trial: Discussions from a Twitter journal club @respandsleepjc (#rsjc)

2020

Christopher Kawala
Anju Anand
Matthew B. Stanbrook

Chronic cough (lasting >8 weeks) is common, affecting 4-16% of adults. 1–3 Patients who have chronic cough despite treatment of their asthma, nonasthmatic eosinophilic bronchitis, gastroesophageal ...

Keywords:

double blind
P2X3 Receptor
Refractory
Internal medicine
Antagonist
Journal club
Medicine
Chronic cough

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations